London – 1 in 5 Fewer May Get Alzheimer’s Due to New Finding

    4

    London – Scientists have found three new major genetic links to Alzheimer’s, affecting up to 20 percent of people with the brain-wasting disease, and said on Sunday it was the most significant such discovery in 15 years.

    Join our WhatsApp group

    Subscribe to our Daily Roundup Email


    Two large studies found that the three new genes join the better-known APOE4 gene as significant risk factors for the most common cause of dementia.

    “If we were able to remove the detrimental effects of these genes through treatments, we could reduce the proportion of people developing Alzheimer’s by 20 percent,” Julie Williams, a professor of Neuropsychological Genetics at Britain’s Cardiff University, told a news conference in London.

    Alzheimer’s disease affects more than 26 million people globally, has no cure and no good treatment. The need for effective remedies is pressing, with the number of cases forecast to go beyond 100 million by 2050.

    Current drugs can only delay the symptoms endured by patients, who lose their memories, the ability to find their way around and to care for themselves.

    Williams, who led one of the two studies published in Nature Genetics, said that in Britain alone, eradicating the effects of the three new genes would mean almost 100,000 people could avoid the disease.

    She said the findings were the most significant genetic discoveries for Alzheimer’s in the 15 years since APOE4 was found to be linked, and said drug companies had shown a keen interest in their research.

    Williams and colleagues at Cardiff’s Medical Research Council Center for Neuropsychiatric Genetics and Genomics carried out a genome-wide association study — a scan of the entire genetic map — involving more than 16,000 people from eight countries. They identified two new genes — called Clusterin and PICALM — that increase the risk of developing Alzheimer’s.

    A second genome-wide study conducted by Philippe Amouyel and colleagues at the Institut Pasteur de Lille in France, studied more than 6,000 people with Alzheimer’s and nearly 9,000 healthy people in France, Belgium, Finland, Italy and Spain. They identified Clusterin and a third gene called CR1.

    Amouyel said the disease risks associated with each gene were difficult to quantify, and said all three genes were relatively common. The scientists also stressed that an as yet unknown combination of many genetic and other environmental factors cause Alzheimer’s.

    The researchers said Clusterin may explain 10 percent of Alzheimer’s cases, PICALM around 9 percent and CR1 4 percent. By comparison, 20 to 25 percent of Alzheimer’s cases are linked to APOE.

    Three gene variations have also been associated with rare, early-onset forms of Alzheimer’s that run in families. Identifying the genes can help researchers understand the underlying causes of a disease and design drugs to fight them.


    Listen to the VINnews podcast on:

    iTunes | Spotify | Google Podcasts | Stitcher | Podbean | Amazon

    Follow VINnews for Breaking News Updates


    Connect with VINnews

    Join our WhatsApp group


    4 Comments
    Most Voted
    Newest Oldest
    Inline Feedbacks
    View all comments
    Anonymous
    Anonymous
    14 years ago

    I would greatly appreciate it if someone can clearly explain gene therapy. Is there really a method to alter a persons gene structure after they were born? Or does it mean somthing else.

    anonymous
    anonymous
    14 years ago

    Gen therapy in Alzheimer is not yet of wide clinical use and if it will be clinically used it will be available in certainly highly specialized neurological clinic. False hope for a devastating disease

    starwolf
    starwolf
    14 years ago

    Actually, gene therapy for Alzheimer’s is not at all in clinical use right now. Not at all.

    As of this article, there are a few genes that we know to be associated with AD. We do not know how to manipulate them for therapy, and we do knot yet know their full effects on the brain.

    As far as post number 2 goes, it is incorrect. We know of several effects of AD pathology in the brain, at least 2 of which affect the structure of the dendrites (which are parts of nerve cells). Although there are methods to correct the pathological structure of the dendrites currently in clinical trials, none of them involve gene therapy. They are a completely different therapeutic approach. Also, the dendritic pathology is only one of those that happen in Alzheimer’s disease, there are several others involved as well. The gene therapy in this case would happen at a much more molecular level.

    In theory, the way that gene therapy works is that a “correct” gene is substituted for the “deficient” gene. To do this, the affected cells need to be targeted by the delivery system. While we understand how to do that in theory, in practice it is much more difficult. The threapy must be tailored to the individual gene affected. In addition, the delivery system (of the new genes) is critical, and we have not yet mastered the technology.